are glp 1 drugs dangerous How long should you take GLP-1 drugs? Study links longer use to lower heart risk Ozempic and Hemophilia: Is It

Thus, all patients were followed from study cohort entry until one of the study outcomes (described below), treatment discontinuation, initiation of a study drug in the comparator group, death from any cause (depending on the outcome), end of registration, or the end of the study period (29 March 2021), whichever came first

doi: 10.1503/cmaj.101281 Summary Keywords sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, type 2 diabetes, metformin, meta-analysis Citation Deng R, Mei K, Song T, Huang J, Wu Y, Yu P, Yan Z and Liu X (2024) First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis

10-year incidence of diabetes and associated risk factors in Greece: the ATTICA study (2002-2012) Rev Diabet Stud

SURMOUNT-5-Studie: Tirzepatid (Mounjaro) Die SURMOUNT-5-Studie verglich direkt die Wirkung von Tirzepatid (Mounjaro) mit Semaglutid (Wegovy)

However, Public (NHS) access is limited